Treating NonAlcoholic Fatty Liver Disease and NonAlcoholic SteatoHepatitis is a possibility.

Corliva™ is a first-in-class, orally administered drug developed to treat NAFLD and NASH by targeting fat accumulation, inflammation and fibrosis.‚Äč
Between 30%-40% of adults in the US have NAFLD and about 3%-12% percent of adults have NASH, a progressive form of NAFLD that can lead to cardiovascular disease, cirrhosis and liver-related mortality.